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Background Experimental data accumulated over more than a
decade indicate that cross-strain protection against inﬂuenza may
be achieved by immunization with conserved inﬂuenza proteins.
At the same time, the efﬁcacy of immunization schemes designed
along these lines and involving internal inﬂuenza proteins, mostly
NP and M1, has not been sufﬁcient.
Objective To test the immunogenicity and protective efﬁcacy of
DNA vaccination with a combination of NP, M1 and NS1 genes
of inﬂuenza virus.
Methods The immunogenicity and protective efﬁcacy of DNA
vaccination with NP, M1 and NS1 was tested in mice and
chickens. Mice were challenged with mouse-adapted viral strains
H3N2 and H5N2 and chicken challenged with avian H5N3
virus.
Results In these settings, wild-type NS1 did not impede the
cellular and humoral response to NP⁄M1 immunization in vivo.
Moreover, addition of NS1-encoding plasmid to the NP⁄M1
immunization protocol resulted in a signiﬁcantly increased
protective efﬁcacy in vivo.
Conclusions The addition of NS1 to an inﬂuenza immunization
regimen based on conserved proteins bears promise. It is feasible
that upon further genetic modiﬁcation of these and additional
conserved inﬂuenza proteins, providing for their higher safety,
expression and immunogenicity, a recombinant vaccine based on
several structural and non-structural proteins or their epitopes will
offer broad anti-inﬂuenza protection in a wide range of species.
Keywords conserved proteins, cross-strain protection, inﬂuenza,
vaccination.
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Introduction
A signiﬁcant effort has been put towards creating a vaccine
capable of inducing a broad anti-inﬂuenza response and
providing protection against multiple viral strains. Differ-
ent approaches have been undertaken with special focus on
the induction of the cytotoxic T lymphocyte (CTL)
response.
1–4
Current inactivated vaccines are not capable of inducing
strong CTL responses
5 and there is a disproportionate differ-
ence between CTL responses to various inﬂuenza epitopes.
3,6
Potentially, an inﬂuenza vaccine that is capable of generating
a balanced CTL response against conserved antigens will
enable a broad spectrum of coverage. Thus, a number of
investigators have focused on conserved internal viral pro-
teins NP and M1.
1,7–10 In particular, a recent study provided
evidence of the signiﬁcant heterosubtypic protection poten-
tial of a DNA⁄adenovirus combination expressing NP pro-
tein.
1 Internal proteins are conserved among inﬂuenza A
strains with maximum amino acid differences of 10.8% for
NP and 24.6% for M1.
11,12 Thus, it is conceivable that an
immune response generated against their epitopes will pro-
vide a certain level of cross-strain protection.
Approaches that would enhance the immune response by
inducing CTLs against NP have received particular atten-
tion (reviewed in Ulmer).
8 Attempts have been made to
employ matrix proteins M1 and M2, but these lead to
mixed results, likely due to defects in their expression and
the poor immunogenicity of these proteins in their wild-
type forms.
7,13–16 There are conﬂicting reports as to whe-
ther an immune response against NP, M1 and M2 proteins
is protective against experimental inﬂuenza infection in
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at least partially successful.
1,7–10,13–19
There has not been a bona ﬁde attempt to investigate the
possible beneﬁts of vaccination with NS1 with the excep-
tion of a study in which plasmids carrying viral genes were
tested separately.
18 NS1 was eliminated early in favour of
HA, NA and NP, which in turn provided strain-speciﬁc
protection based mostly on the humoral antibody
response.
17–19 NS1 protein is well conserved and expressed
early in the infection. A plethora of immune modulating
functions is assigned to NS1, including inhibition of IFN-a
and -c.
20–24 Thus, if NS1 immunization is shown to be of
value, it will likely need to be modiﬁed to enable its inclu-
sion into a recombinant vaccine product.
CTL responses against NS1 have been detected in per-
ipheral blood mononuclear cells (PBMC) from healthy
donors. This testiﬁes to the generation of anti-NS1 cellular
immunity and to the existence of strong immune memory
against this protein.
25 Alignment of NS1 gene sequences in
strains from different hosts reveals that its functional
domains are well conserved.
26
Thus, in addition to NP and M1, non-structural NS1 pro-
tein is also capable of inducing a broad and long-term
immune response and is a promising candidate for incorpor-
ation into a broad-spectrum inﬂuenza vaccine. In this report
we present data demonstrating the protective effect of
immunization with a combination of DNA plasmids enco-
ding inﬂuenza NP, M1 and NS1. This is the ﬁrst demonstra-
tion that the protective beneﬁt achieved in vivo through
vaccination with a combination of NP, M1 and NS1 inﬂu-
enza proteins is superior to the separate use of any of these
immunogens or to the double combination of NP and M1.
Materials and methods
Generation of NP, M1 and NS1 expression
plasmids
Expression plasmids carrying conserved inﬂuenza NP, M1
or NS1 genes (pNP, pM1 and pNS1) were constructed by
insertion of the PCR-ampliﬁed full viral gene sequences
into the EcoRI site of pCAGGS vector.
27 Viral sequences
were as follows: NP from strain A⁄WSN⁄33-H1N1 (identi-
cal to A⁄PR⁄8⁄34-H1N1 on the amino acid level; P.O.
Ilyinskii, A.G. Prilipov and A.M. Shneider, unpublished
data), M1 from the same strain and NS1 from strain
A⁄PR⁄8⁄34-H1N1 (accession numbers: V01084, L25818
and J02150). 293T cells were transfected with plasmid
DNAs using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s directions using
either 1 or 2.7 lg of DNA per 3 cm cell culture dish.
Deletion mutants of NS1 in pCAGGS were generated by
site-directed mutagenesis. The ﬁrst mutant was designed to
contain the deletion of amino acids 34–41 (designated as
NS1del34) and the second one to contain a deletion of amino
acids 34–41 and 184–188 (designated as NS1del34⁄184).
Upon selection and sequence veriﬁcation, mutant NS1 forms
were tested for their expression in 293T cells.
Immunization with pNP, pM1 and pNS1
combination in vivo
Four micrograms of pNP, pM1 and pNS1 in 100 ll of phos-
phate-buffered saline (PBS) was injected intramuscularly per
mouse per vaccination. For the H3N2 challenge, Balb⁄c mice
were divided into three groups (29 animals each): control
(or group 1, injected with pCAGGS), group 2 (injected with
pNP⁄pM1⁄pNS1wt mixture) and group 3 (injected with
pNP⁄pM1⁄pNS1del34). For the challenge with H5N2 virus,
experimental groups were immunized either with: a combi-
nation of three plasmids encoding for NP, M1 or NS1 inﬂu-
enza proteins; with each of these plasmids separately; empty
vector; or untreated control. The size of the experimental
groups was 19–21 animals per group with the exception of
the control group that comprised 16 animals. Mice were sub-
jected to immunization with plasmid DNA three times with
14 day intervals in between. Animal survival, levels of anti-
viral CTLs and antibody generation were monitored.
CTL response in vivo
Six days after the third DNA vaccination, three mice from
each group were killed, their splenocytes puriﬁed and
stimulated (10
8 total, plated at 5 · 10
6⁄ml) in vitro by
co-cultivation at a 10:1 ratio with the syngeneic feeder
splenocytes infected with inﬂuenza A⁄PR⁄8⁄34 (H1N1)
virus (taken from healthy mice, infected at MOI 20 PFU⁄-
cell for 24 h and UV-inactivated). High levels of NP, M1
and NS1 expression in target spleen cells was demonstrated
by immunoblotting with virus protein-speciﬁc antibodies
(data not shown).
Splenocytes isolated from mice infected intranasally twice
at 3-week intervals with a sublethal dose of inﬂuenza A⁄ Ai-
chi⁄2⁄68 (H3N2) virus were used as a positive CTL control.
Stimulated splenocytes were incubated for 16 days. Mouse
p815 cells infected with inﬂuenza A⁄PR⁄8⁄34 virus (MOI 20
PFU⁄cell) for 24 h were used as a target and cytotoxic activ-
ity was measured by lactate dehydrogenase release (CytoTox
96 Kit; Promega, Madison, WI, USA). Target p815-infected
cells (0.3 · 10
5⁄well) were mixed with twofold dilutions of
stimulated effector cells starting with 3.0 · 10
6 cells⁄well and
incubated for 6 h at 37 C. CTL activity as % of cell lysis was
calculated by the following formula: (experimental
release ) spontaneous release)⁄(maximum release ) sponta-
neous release) · 100.
Humoral anti-viral response in immunized mice
The level of anti-NP and M1 antibodies was determined
as follows. Serum samples of DNA-vaccinated mice were
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were assayed in a direct ELISA against whole disrupted inﬂu-
enza virus A⁄PR⁄8⁄34 adsorbed onto a plate as described
earlier using a viral suspension in PBS normalized for M1
concentration of 0.7 lg⁄ml (coating with 100 ll⁄well for
15 h at 8 C).
28 Twofold dilutions of animal sera were added
to the pre-absorbed plates and virus-speciﬁc antibodies were
measured employing anti-mouse IgG-horseradish peroxi-
dase conjugate using 3,3’,5,5’-tetramethylbenzidine (TMB)
substrate. Radioimmunoprecipitation assay (RIPA) was
performed using whole-cell lysate of Madin-Darby canine
kidney (MDCK) cells infected with inﬂuenza A⁄WSN⁄33
strain (H1N1) incubated with
14C yeast lysate.
Mouse inﬂuenza viruses and animal infection
The mouse-adapted variant of strain A⁄Aichi⁄2⁄68 (H3N2)
was obtained from Dr V. Knight (Baylor College). Inﬂuenza
viruses A⁄PR⁄8⁄34 and A⁄WSN⁄33 (H1N1) were obtained
from the virus collection of Ivanovsky Institute of Virology,
Russia. Viruses were propagated in 10-day-old embryonated
chicken eggs. The virus-containing allantoic ﬂuid was
stored at )70 C and titrated in chicken embryo or MDCK
cells. Ether-anaesthetized BALB⁄c mice (10–12 g) were
infected intranasally with 50 ll of PBS-diluted allantoic
ﬂuid containing 10 or 100 LD50 of A⁄Aichi⁄2⁄68-MA, 9 or
10 days after the ﬁnal boost. Each experimental group con-
tained 10 animals. Protection was measured by monitoring
survival and body weight, which was assessed throughout
an observation period of 21 days. Severely affected mice
were killed. A similar experimental set-up was used for the
challenge with A⁄Mallard⁄Pennsylvania⁄10218⁄84 (H5N2).
This avian inﬂuenza virus was obtained from the virus
depository of the Virology Department of St. Jude Chil-
dren’s Research Hospital (Memphis, TN, USA) and was
adapted to mice by lung-to-lung passage.
29 For both A⁄
Aichi⁄2⁄68 and A⁄Mallard⁄Pennsylvania⁄10218⁄84 viruses,
1L D 50 was equal to 100–1000 TCID50. Experimental infec-
tion was performed 9 days after the second immunization
(5 LD50). Lung tissues from H5N2-infected animals (two
from each group) were taken at day 4 after infection for
viral titre evaluation. Viral titres were measured by focus
assay in MDCK cells that were grown in 24-well plates and
incubated with 0.5 ml⁄well of 10-fold sample dilutions.
After a 60-min absorption at RT, the virus inoculum was
removed, cells washed and covered with 1% agarose. 50 h
later, cells were ﬁxed and incubated for 1 h with anti-
inﬂuenza virus antibodies and visualized using peroxidase
staining. Stained foci (PFU) were counted and titres calcu-
lated by the routine Reed & Muench method.
Determination of virus virulence in chickens
The virulence of A⁄Tern⁄South Africa⁄61 (H5N3) for
chickens was evaluated as follows. Four-week-old chickens
(Lohmann Brown, line PK-13) were infected by intra-
muscular injections at different dosages of virus in the
range of 10–10 000 PFU⁄chicken. It was determined that
this strain was lethal in a dose range of 10–100 PFU⁄-
chicken delivered intramuscularly. Infected birds lost their
appetite, had rufﬂed feathers and manifested signs of cen-
tral nervous system pathogenesis, such as inability to stand
and spontaneous head twisting and succumbing to the dis-
ease within 5–8 days. The birds also shed high concentra-
tions of virus and the virus titres in their cloak swabs
reached up to 10
3–10
4 PFU⁄swab on day 7 post-infection.
Vaccination and experimental infection in avian
model
Seventeen-day-old Lohmann Brown chickens were injected
intramuscularly two times at 12-day intervals with vaccine
DNA (5 lg⁄chicken of each DNA plasmid in 200 ll PBS
per vaccination). Three groups of 10 chickens were used,
these being immunized with empty vector, pNP⁄pM1 or
pNP⁄pM1⁄pNS1 combinations. On day 9 following the
second vaccination, chickens were infected intramuscularly
with 10 LD50 of A⁄Tern⁄SA⁄61 virus (approximately
50–100 PFU⁄chicken). On day 7 following infection, blood
samples and cloak swabs were prepared and virus titres
were measured by virus focus assay in MDCK cells, as
described above. Survival of chickens in each group was
monitored daily for 15 days following infection.
Statistical methods
Standard error (SE) of a percentage value was determined
by the formula: SE =  p(100 ) p)⁄n, where p is percentage
value and n is the number of animals used, similar to a
previously described study.
30 The signiﬁcance between two
percentage values (with probability 0.95) was: t = p1 )
p2⁄ SE1
2±SE2
2 ‡ 2.0. Animal survival was compared using
log-rank test (PROC LIFETEST, SAS(R) statistical pack-
age). The differences at P-value below 0.05 were considered
signiﬁcant.
Results
Expression of conserved viral proteins NP, M1 and
NS1 in vitro
Conserved wild-type inﬂuenza genes NP, M1 and NS1 were
derived from H1N1 virus strains. All were shown to be efﬁ-
ciently expressed in vitro (data not shown). We also con-
structed two mutant variants of NS1 protein, designed to
eliminate the effector regions of its immunosuppressive
functions. The expression of these mutants was severely
impaired compared to the robust expression of wild-type
NS1 (Figure 1). Only a minor band of the NS1del34 pro-
tein was detected. No NS1-speciﬁc bands were revealed in
cells transfected with the double mutant pNS1del34⁄184
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of bands produced by pNS1wt and pNS1del34 showed that
expression of the mutant NS1 form was 100 fold lower
than that of NS1wt. When the proteosomal stability of
NS1wt and NS1del34 was assayed using proteosomal inhib-
itor MG132, there was no additional stabilization and pro-
tein accumulation as seen for both mutant NS1 forms
(data not shown). As it was obvious that pNS1del34 is
unlikely to have any substantial activity in vivo it was
employed throughout this study as a plasmid DNA control
of immunization with pNS1.
Antiviral CTL response in immunized mice
Three groups of mice were vaccinated thrice intramuscular-
ly with either empty vector (placebo) or with combinations
of pNP⁄pM1⁄pNS1 or pNP⁄pM1⁄pNS1del34. The results
of CTL measurement in animals vaccinated three times are
shown in Figure 2. Signiﬁcant CTL responses to inﬂuenza
virus developed in all vaccinated animals. At the E⁄T ratio
of 50:1–100:1, the CTL response in animals immunized
with wild-type pNP, pM1 and pNS1 reached 70–90% of
target cell lysis and was similar to CTL activity developed
in native infection control (mice inoculated twice with a
sublethal dose of inﬂuenza A⁄Aichi⁄2⁄68 virus), while the
CTL response in mice vaccinated with the mixture contain-
ing pNS1del34 was somewhat lower at these high E⁄T
ratios.
Humoral anti-viral response in immunized mice
Mouse antibody titres were determined in the sera of vac-
cinated animals using an ELISA against whole disrupted
inﬂuenza virus (Figure 3). Unvaccinated mice infected with
inﬂuenza (positive control) produced a prominent signal at
serum dilutions as high as 1:128–1:256. A marked signal
was also detected in mice vaccinated with pNP⁄pM1⁄pNS1
or pNP⁄pM1⁄pNS1del34 mixtures at dilutions of 1:64–
1:128. Notably, the difference in the NS1 form utilized
herein does not affect the antibody titre against the whole
virus as the latter does not contain NS1. Sera from the
pNP⁄pM1⁄pNS1-immunized group showed strong reactiv-
ity against NP and lower reactivity against M1 and NS1 in
RIPA; sera from the pNP⁄M1⁄pNS1del34-immunized
group showed similar reactivity to NP and M1, while the
activity against NS1 was absent (data not shown).
Protective effect in experimentally infected mice
Mice vaccinated twice with both combinations of pNP,
pM1 and pNS1 (differing only in the type of NS1 used)
NS1del34 NS1wt
12345  
Figure 1. Expression of wild-type NS1 and its mutants in vitro. Total
cell extract was immunoblotted with anti-NS1 polyclonal guinea-pig
serum. Lane 1, NS1wt; lanes 2⁄3, NS1del34⁄184; lanes 4⁄5, NS1del34.
Amount of protein in lane 1 is one-ﬁfth of the amounts used in lanes
2–5. Lanes 2⁄3 and 4⁄5: 1⁄2.7 lg of plasmid was used for
transfection.
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Figure 2. CTL response in animals immunized with pNS1⁄pNP⁄pM1
combinations. BALB⁄c mice were injected three times at 14-day
intervals. Positive control – infection with sublethal dose of
A⁄Aichi⁄2⁄68 virus; negative control – placebo immunization.
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Figure 3. Antibody reactivity of sera from vaccinated animals. Twofold
dilutions of sera were incubated with plated antigen (whole-disrupted
inﬂuenza virus A⁄PR⁄8⁄34), and level of antiviral antibodies was
determined as described in the text.
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mental infection with inﬂuenza. All animals were chal-
lenged intranasally with the mouse-adapted variant of
strain A⁄Aichi⁄2⁄68 (H3N2) at 10 or 100 LD50. Body
weight, lung pathology and overall mortality were assessed.
Normal body gain was observed up to the time period fol-
lowing the second vaccination and preceding viral infec-
tion. These data indicate the absence of any visible toxicity
of the DNA vaccine injections.
Immediately upon viral infection, a marked body weight
reduction was observed in all infected groups. This reduc-
tion was fatal in placebo-immunized animals at both 10
(Figure 4) and 100 LD50 (data not shown), but was less
dramatic in DNA vaccinated groups. The weight reduction
in these groups was slower and body weight started to
increase 3–4 days after virus infection, indicating recovery.
The body weight gain started earlier and developed more
rapidly in mice vaccinated with DNA plasmids encoding all
three wild-type proteins. Less than a week after the chal-
lenge (Figure 4, day 30) the difference between pNP⁄pM1⁄
pNS1 and pNP⁄pM1⁄pNS134 became statistically signiﬁ-
cant (P £ 0.05).
Examination of mouse lungs was performed on day 6
following viral infection in the group that was infected with
10 LD50. Two mice from each experimental group – non-
vaccinated (placebo), vaccinated with either pNP⁄pM1⁄
pNS1wt or pNP⁄pM1⁄pNS1del34 and uninfected – were
killed, their lungs taken and photographed (Figure 5, repre-
sentative results are shown). Lungs of unvaccinated mice
had clear signs of fatal haemorrhagic inﬂammation. The
inﬂammation in DNA-vaccinated mouse lungs was signiﬁ-
cantly less than in the lungs from the placebo control
group. The most signiﬁcant reduction in lung pathology
was observed in mice from the group vaccinated with a
combination of plasmids encoding wild-type NP, M1 and
NS1. The external appearance of lungs from this animal
group was similar to those of mock-infected animals
(Figure 5).
Full results of animal survival following the challenge
with H3N2 Aichi strain are presented in Table 1. DNA
immunization with the plasmid combination of wild-type
NP, M1 and NS1 proteins resulted in complete protection
in the animals infected with 10 LD50 and showed some
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Figure 4. Body weight gain⁄loss in mice immunized with combinations
of pNP⁄pM1⁄pNS1 and challenged with 10 LD50 of inﬂuenza virus.
Mean weights (±SD) are shown for each group. *Time interval in which
the difference between pNP⁄pM1⁄pNS1 and pNP⁄pM1⁄pNS1del34-
immunized groups was statistically signiﬁcant (P < 0.05).
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Figure 5. Lung pathology (day 6 after infection) in vaccinated and
experimentally infected mice from the same experimental groups
described in the legend to Figure 4. Haemorrhagic inﬂammation areas
are shown by arrows.
Table 1. Protective efﬁcacy of DNA immunization with conserved
proteins of inﬂuenza against experimental infection with
A⁄Aichi2⁄68 (H3N2) virus in mice
Immunization with
Lethal outcome of inﬂuenza
virus experimental infection
in mice*
10 LD50 100 LD50
pNP⁄pM1⁄pNS1 0⁄10 6⁄10
pNP⁄pM1⁄pNS1del34 4⁄10 8⁄10
Placebo 10⁄10 10⁄10
*Numerator: number of dead mice; denominator: number of mice
in the group. Survival as of 21 days post-infection is shown.
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cantly less protection was provided by vaccination using a
combination of NP, M1 and NS1del34. The survival differ-
ence between pNP⁄pM1⁄pNS1 and pNP⁄pM1⁄pNS1del34-
immunized groups was statistically signiﬁcant (P < 0.05)
following viral challenge with 10 LD50.
A separate experiment was performed in the mouse
model using a similar scheme of immunization followed by
challenge with a different inﬂuenza virus strain, A⁄Mal-
lard⁄Pennsylvania⁄10218⁄84 (H5N2, of avian origin, but
mouse-adapted; see Materials and methods). Six groups of
Balb⁄c mice were inoculated either with a pNP⁄pM1⁄pNS1
combination or with each of the plasmids separately. Vac-
cination was performed twice and was followed by viral
challenge with 5 LD50. The data on animal survival are
shown in Figure 6. The only group of animals that showed
noticeable and statistically signiﬁcant protection against 5
LD50 H5N2 challenge was immunized with the
pNP⁄pM1⁄pNS1 combination differing signiﬁcantly from
pNP- and pM1-immunized groups (log-rank test, P £ 0.05)
as well as from pNP-, pM1- and pNS1-immunized groups
combined (log-rank test, P £ 0.01). This observation was
further supported by the data on viral titre from infected
animals (Table 2). While pNP-immunized animals also
showed a decrease in viral titre (which in this group did
not translate into elevated survival), it was most profoundly
manifested in the group immunized with the three-plasmid
combination.
Immunization and protective effect in experiment-
ally infected chickens
We were especially interested in testing the effects of
immunization with the combination of pNP⁄pM1⁄pNS1 in
the avian model, which would employ another antigenically
unrelated viral strain (H5N3) for the challenge. Moreover,
it was imperative to test in a straightforward manner if the
addition of wild-type pNS1 to pNP⁄pM1 combination pro-
vides an additional beneﬁcial effect in vivo. Thus, we con-
ducted a vaccination and experimental challenge
experiment in the avian model using immunization either
with pNP⁄pM1 or with pNP⁄pM1⁄pNS1.
Following the determination of the lethal infectious dose
in the chicken model (see Materials and methods) we
assessed the protective effect of DNA vaccination with these
plasmid combinations using challenge with inﬂuenza H5N3
A⁄Tern⁄SA⁄61 virus. Viral titres in the infected birds were
measured and their survival determined. We did not detect
virus in blood samples in all of the chickens examined
(3⁄group). Thus, there was no measurable viraemia at this
stage of infection. However, virus was observed in cloak
swabs taken at the same time. Signiﬁcant virus titres (10
2–
10
4 PFU⁄swab) were detected in the cloak of placebo-
treated chickens. No virus was detected in the cloaks of
chickens vaccinated with pNP⁄pM1 or pNP⁄pM1⁄pNS1
DNA combinations.
The data documenting the survival of experimentally
infected chickens are shown in Figure 7. All birds vaccin-
ated with an empty vector (placebo) died by day 8 follow-
ing challenge. Marginal protection (10–20%) was observed
in the group of chickens that were vaccinated with
pNP⁄pM1 and a more prominent protective effect (40%)
was observed in the group that was vaccinated with the
pNP⁄pM1⁄pNS1 combination. The effect of
pNP⁄pM1⁄pNS1 vaccination was statistically signiﬁcant
compared to placebo according to the log-rank test
(P £ 0.02), while vaccination with pNP⁄pM1 did not result
in a statistically signiﬁcant effect. In addition to mortality
decrease, vaccination with pNP⁄pM1⁄pNS1 appeared to
delay the fatal disease. Birds in this group died 1–3 days
later than in the placebo group. No such effect was
observed in the pNP⁄pM1-vaccinated group.
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Figure 6. Survival of mice vaccinated with the combination of pNP,
pM1 and pNS1 after challenge with 5 LD50 of H5N2 inﬂuenza virus
strain A⁄Mallard⁄Pennsylvania⁄10218⁄84.
Table 2. Titres of inﬂuenza virus in lungs of mice on day 4 after
infection with 5 LD50 of A⁄Mallard⁄Pennsylvania⁄10218⁄84
Animals immunized
with
Animals
tested
Geometric mean titre ± SE
(log TCID50⁄lung)*
pNP 4 5.93 ± 0.13
pM1 4 6.6 ± 0.18
pNS1 4 6.6 ± 0.18
pNP⁄pNS1⁄pM1 4 5.78 ± 0.16
pCAGGS 4 6.3 ± 0.18
Intact 4 6.2 ± 0.28
*Titration was done in MDCK cells (6 wells⁄dilution). SE calculation
is described in the text.
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Many research groups including ours have repeatedly dem-
onstrated that internal proteins of inﬂuenza virus may pro-
vide for some degree of protection against infection.
1,7,9,10,17–
19,30 Moreover, immunization against NP was thought to
carry the greatest promise of generating a broad-spectrum
anti-inﬂuenza vaccine.
8,31 At the same time, another con-
served inﬂuenza protein, NS1, has not been studied as a
component of a recombinant vaccine, possibly due to the
capacity of this protein to suppress multiple immune
response pathways.
20–24 However, if the beneﬁts of NS1
incorporation into an immunization regimen are demonstra-
ted, it would be very important to generate a safe and immu-
nologically effective NS1 variant. Therefore, we attempted to
construct NS1 mutants designed to abrogate known determi-
nants of its immunosuppressive functions.
While wild-type NS1 was efﬁciently expressed, none of
the NS1 mutants showed strong expression in vitro. In fact,
only one, NS1del34, was veriﬁably detected. The extremely
low expression level of this mutant cannot be attributed to
the higher degree of its proteosomal degradation as the
proteosome inhibitor, MG132, did not increase the level of
NS1del34 (otherwise, one could argue that mutant NS1
may be misfolded and thus rapidly degraded by proteo-
some-dependent mechanisms and ultimately, efﬁciently
presented by the major histocompatibility complex class I
pathway). Moreover, the region encompassing amino acids
34–41 is generally important for NS1 expression as a
mutant that has only two substitutions in amino acids 38
and 41 was also not expressed in vitro in a proteosome-
independent manner. This was not related to epitope
recognition as this novel NS1 mutant was fused to peptide
tags on both N- and C-termini, and antibodies to these
tags were used for NS1 detection. Furthermore, we have
demonstrated that the expression of this and similar NS1
mutants is markedly hindered. Apparently, this region of
the NS1-encoding RNA possesses a conserved sequence that
plays an important role in its stabilization and translation
initiation (Ilyinskii et al., unpublished data).
The immunogenicity of the plasmid combinations
pNP⁄pM1⁄pNS1 and pNP⁄pM1⁄pNS1del34 was studied in
the mouse model. Both of these combinations efﬁciently
induced CTLs in vivo. Notably, the anti-inﬂuenza CTL
response in naturally infected humans is known to develop
mainly against NP, M1 and NS1.
3,25,32
The protective capacities of vaccination with these plas-
mid combinations were assessed using intranasal challenge
with 10 or 100 LD50 of mouse lung-adapted A⁄Aichi⁄2⁄68
(H3N2) virus. Body weight, lung pathology and overall
survival were monitored. Thus it was clear that immuniza-
tion with a combination of pNP⁄pM1⁄pNS1 resulted in a
signiﬁcant protective beneﬁt. Such an effect was less evident
for the pNP⁄pM1⁄pNS1del34-immunized group.
Due to the very low expression level ( 100-fold less
than NS1wt) of NS1del34, one may provisionally count the
latter group as immunized with only pNP⁄pM1, but with
the same overall DNA quantity as the pNP⁄pM1⁄pNS1-
immunized group. If such an assumption is correct, then it
is clear that the addition of NS1wt provides a clear beneﬁt
in terms of animal survival, which was statistically signiﬁ-
cant for the groups infected with 10 LD50 (P < 0.05). The
results reported earlier demonstrated no protection when
NS1 alone was used for immunization.
18
Furthermore, we employed a more stringent challenge of
similarly immunized mice with 5 LD50 of antigenically
unrelated H5N2 virus that originated in birds but adapted
to mice by serial passages, a process not dissimilar from
the one that may result in the human adaptation of an
avian pandemic strain. In this system, the only immuniza-
tion regimen that was beneﬁcial also comprised
pNP⁄pM1⁄pNS1, while these plasmids when used individu-
ally provided no alleviation of disease.
It was important to test whether such a protective effect
could be observed in a different host and against a very
divergent inﬂuenza virus strain. Therefore, we conducted
an experiment in a chicken model using antigenically un-
related H5N3 inﬂuenza virus. Two vaccine combinations
were employed: pNP⁄pM1 and pNP⁄pM1⁄pNS1. Of these,
only the latter combination has shown a protective beneﬁt
in the avian system. These results conﬁrm that the inclu-
sion of NS1 into the vaccination regimen provides an addi-
tional beneﬁt against morbidity and mortality in the
experimental setting.
In this experimental series we have used a hetero-subtypic
challenge upon the homologous immunization with subop-
timal DNA vectors. Moreover, we have deliberately used
two immunizations in our protection studies (compared to
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Figure 7. Survival of chickens vaccinated and experimentally infected
with H5N3 inﬂuenza virus. Birds unvaccinated and vaccinated with
either pNP⁄pM1 or pNP⁄pM1⁄pNS1 were challenged with lethal doses
of H5N3 A⁄Tern⁄SA⁄61 avian inﬂuenza virus as described in the text.
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move away from the idealized laboratory-type regimens and
towards more realistic vaccination schedules (in addition,
DNA is known to be a much better prime than booster and
it is unlikely that the third DNA immunization will result
in a dramatic elevation of immune responses). While the
NP⁄M1⁄NS1 combination has, in our view, shown some
promise for cross-strain protection, this immunization regi-
men and vectors used herein may be signiﬁcantly improved.
The use of adenoviral vectors and heterologous prime-boost
appears to be particularly promising.
1,33,34 It is not improb-
able to reach a high level of protection using exclusively
immunization with conserved inﬂuenza viral proteins or
their derivatives, especially if newly developed approaches
are used in concert, including novel adjuvants, vectors and
other immune response augmentation strategies.
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